Get notified when MLYS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Security Interest In Substantially All Assets Including IP (new) — Lenders hold senior claim on core technology and operating assets; default could trigger foreclosure and liquidation of collateral, potentially ending operations.
  • Material Adverse Change to Lorundrostat Is Explicit Loan Default Trigger (new) — Any material adverse change or withdrawal event for the lead product candidate triggers acceleration of all debt obligations including make-whole premiums.
  • Company Does Not Expect to Generate Sufficient Cash Flow to Service Debt (new) — Management states business will not generate cash flow from operations to service debt in the foreseeable future; may require asset sales, debt restructuring, or dilutive equity raises.
NASDAQ: MLYS Mineralys Therapeutics, Inc. 10-Q

MLYS: net income -$241.1M. MLYS pays to eliminate lorundrostat royalties, draws debt as Dec 2026 FDA decision nears

Filed August 11, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 12, 2025 · ~2 min read

Key Changes

  • high

    Paid Tanabe $200M upfront in June 2026 to eliminate all future royalty obligations (previously mid-single-digit to 10% of net sales) and convert the license to perpetual, royalty-free; expensed immediately as R&D, driving six-month operating loss to $291.4M vs. $91.2M prior year.

    Legal Proceedings: Tanabe license amendment verify on EDGAR →
  • high

    Drew $100M from new up to $500M senior secured term loan (SOFR + 5.50%, 9.15% at inception); remaining up to $400M tranches contingent on FDA approval by April 2027 and sales milestones. Loan secured by substantially all assets including IP; default triggers include material adverse change to lorundrostat.

    Notes: Senior secured term loan verify on EDGAR →
  • high

    NDA submitted December 2025, accepted by FDA with PDUFA target action date of December 22, 2026. Management states current $661.4M cash position sufficient to fund operations including commercial launch for at least twelve months.

    MD&A: NDA submission and PDUFA date verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.

Partner

Trade MLYS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 12, 2026 · How we verify